Ruth Schneider
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ruth Schneider has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Barbara Bellenberg
Institute of Neuroradiology, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany
10 shared publications - Carsten Lukas
Ruhr University Bochum, St. Josef Hospital, Institute of Neuroradiology, Bochum, Germany
10 shared publications - Ralf Gold
Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany
8 shared publications Carsten Lukas
Institute of Neuroradiology, Ruhr-University Bochum, St. Josef-Hospital , Bochum 44791
7 shared publicationsRalf Gold
Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital , Bochum 44791
6 shared publicationsBarbara Bellenberg
Institute of Neuroradiology, St. Josef Hospital Ruhr University Bochum Bochum Germany
5 shared publications
Latest Publications
- Open Access
- 18 April 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (3) , fcag129
Longitudinal changes of choroid plexus volumes and MRI ratios in multiple sclerosis
This longitudinal study aimed to identify the predictive role of choroid plexus enlargement for disability progression and its association with tissue damage in early multiple sclerosis patients. Forty patients with clinically isolated syndrome or early relapsing–remitting multiple sclerosis underwent brain MRI scanning at baseline, after 2 and after 6–8 years. FreeSurfer segmentation was used for brain volume estimation, and the choroid plexus was segmented by use of an independent automated segmentation tool. MRI ratios (T1 weighted through fluid attenuated inversion recovery image values) were calculated after calibration and subtracting lesion masks. Lesion masks were eroded to obtain both lesion rims and centres, for which mean ratios were extracted in addition to normal-appearing white matter. Expanded Disability Status Scale and disease duration were collected from neurological examination. Between baseline and last follow-up, choroid plexus volumes increased, and MRI ratios in lesions decreased significantly, which was dominated by the decrease in clinically isolated syndrome rather than relapsing–remitting patients and more pronounced in lesion rims than in their centre. Choroid plexus volumes were significantly related to MRI ratios within rims of lesions at baseline and within lesion centres after 6–8 years, but not within normal-appearing white matter. No associations between choroid plexus volumes or ratios and disability were found. We observed longitudinal changes of both choroid plexus enlargement and MRI ratios over 6–8 years in early multiple sclerosis patients. Choroid plexus enlargement seemed involved in the dynamic development of lesion destructivity.
- 18 April 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (3) , fcag129
Open AccessLongitudinal changes of choroid plexus volumes and MRI ratios in multiple sclerosis
This longitudinal study aimed to identify the predictive role of choroid plexus enlargement for disability progression and its association with tissue damage in early multiple sclerosis patients. Forty patients with clinically isolated syndrome or early relapsing–remitting multiple sclerosis underwent brain MRI scanning at baseline, after 2 and after 6–8 years. FreeSurfer segmentation was used for brain volume estimation, and the choroid plexus was segmented by use of an independent automated segmentation tool. MRI ratios (T1 weighted through fluid attenuated inversion recovery image values) were calculated after calibration and subtracting lesion masks. Lesion masks were eroded to obtain both lesion rims and centres, for which mean ratios were extracted in addition to normal-appearing white matter. Expanded Disability Status Scale and disease duration were collected from neurological examination. Between baseline and last follow-up, choroid plexus volumes increased, and MRI ratios in lesions decreased significantly, which was dominated by the decrease in clinically isolated syndrome rather than relapsing–remitting patients and more pronounced in lesion rims than in their centre. Choroid plexus volumes were significantly related to MRI ratios within rims of lesions at baseline and within lesion centres after 6–8 years, but not within normal-appearing white matter. No associations between choroid plexus volumes or ratios and disability were found. We observed longitudinal changes of both choroid plexus enlargement and MRI ratios over 6–8 years in early multiple sclerosis patients. Choroid plexus enlargement seemed involved in the dynamic development of lesion destructivity.
- Open Access
- 11 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (9) , e214217
Multiple Sclerosis Relapse Treatment During Pregnancy and Offspring Functional and Structural Neurodevelopment
High-dose methylprednisolone (MP) is the global standard for treating pregnancy-associated relapses in multiple sclerosis (MS). Given that glucocorticoids cross the placenta and may interfere with fetal brain development, concerns remain about their long-term safety. This study assessed whether in utero MP exposure as part of MS relapse therapy affects neurodevelopment in school-aged children. In this cross-sectional, 2-center study, term-born children with prenatal exposure to MP due to maternal MS relapse treatment were compared with a nonexposed reference group of children, all born to mothers with MS. Participants were primarily identified using the German MS and Pregnancy Registry and assessed at tertiary MS centers. The primary outcome was global cognitive ability, measured using a standardized intelligence test. Secondary outcomes included attention, behavior, motor performance, and electrocortical activity at rest. Structural brain development was assessed using high-resolution MRI, including voxel-based and surface-based morphometry. Deviations from chronological brain age were quantified using a machine learning-based framework. Statistical associations were examined using linear regression models. The MP-exposed group (n = 30; mean age 9.6 years; 37% female) and the reference group (n = 30; mean age 10.0 years; 40% female) were comparable with respect to demographic and perinatal characteristics. The median cumulative MP dose was 5 g (Q1-Q3: 3-7.5), predominantly administered during the second trimester. Global IQ did not differ between groups (MP: 103.0; 95% CI: 99.2-106.8 vs reference: 101.5; 95% CI: 97.6-105.3). After correction for multiple comparisons, no group differences emerged in secondary neuropsychological outcomes or electrocortical parameters. MRI analyses revealed no differences in gray matter volume, cortical thickness, gyrification, or chronological brain age. In spite of theoretical concerns that MP exposure during pregnancy might lead to alterations in neurodevelopment, this was not found to be the case in this cohort, with most exposures occurring during the second trimester. However, this study was not powered to detect subtle associations in secondary analyses or to draw definitive conclusions regarding potential dose-response relationships. Given the remaining uncertainties, MP should be used with caution at the lowest effective dose until larger follow-up studies provide further clarity.
- 11 November 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (9) , e214217
Open AccessMultiple Sclerosis Relapse Treatment During Pregnancy and Offspring Functional and Structural Neurodevelopment
High-dose methylprednisolone (MP) is the global standard for treating pregnancy-associated relapses in multiple sclerosis (MS). Given that glucocorticoids cross the placenta and may interfere with fetal brain development, concerns remain about their long-term safety. This study assessed whether in utero MP exposure as part of MS relapse therapy affects neurodevelopment in school-aged children. In this cross-sectional, 2-center study, term-born children with prenatal exposure to MP due to maternal MS relapse treatment were compared with a nonexposed reference group of children, all born to mothers with MS. Participants were primarily identified using the German MS and Pregnancy Registry and assessed at tertiary MS centers. The primary outcome was global cognitive ability, measured using a standardized intelligence test. Secondary outcomes included attention, behavior, motor performance, and electrocortical activity at rest. Structural brain development was assessed using high-resolution MRI, including voxel-based and surface-based morphometry. Deviations from chronological brain age were quantified using a machine learning-based framework. Statistical associations were examined using linear regression models. The MP-exposed group (n = 30; mean age 9.6 years; 37% female) and the reference group (n = 30; mean age 10.0 years; 40% female) were comparable with respect to demographic and perinatal characteristics. The median cumulative MP dose was 5 g (Q1-Q3: 3-7.5), predominantly administered during the second trimester. Global IQ did not differ between groups (MP: 103.0; 95% CI: 99.2-106.8 vs reference: 101.5; 95% CI: 97.6-105.3). After correction for multiple comparisons, no group differences emerged in secondary neuropsychological outcomes or electrocortical parameters. MRI analyses revealed no differences in gray matter volume, cortical thickness, gyrification, or chronological brain age. In spite of theoretical concerns that MP exposure during pregnancy might lead to alterations in neurodevelopment, this was not found to be the case in this cohort, with most exposures occurring during the second trimester. However, this study was not powered to detect subtle associations in secondary analyses or to draw definitive conclusions regarding potential dose-response relationships. Given the remaining uncertainties, MP should be used with caution at the lowest effective dose until larger follow-up studies provide further clarity.
- Open Access
- 27 October 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (6)
Eomesodermin-expressing CD4 Th cells and association with multiple sclerosis progression and brain atrophy
Multiple sclerosis is a chronic inflammatory disease affecting the central nervous system. While treatment made huge advances, progression remains a challenge. Eomesodermin+ Th cells are associated with cytotoxicity, neuroinflammation and disease progression in secondary progressive multiple sclerosis. We performed a prospective longitudinal study over one year to investigate the role of Eomesodermin+ T cells in multiple sclerosis progression and neurodegeneration. Patients underwent detailed clinical assessment and immunophenotyping. In a subcohort of patients, cross-sectional magnetic resonance imaging using voxel-based morphometry was performed. Frequencies of Eomesodermin+ Th cells could differentiate between patients with secondary and primary progressive multiple sclerosis and correlated with B-cells in secondary progressive multiple sclerosis. Secondary progressive patients experiencing a subjective worsening of disease activity showed higher baseline frequencies of Eomesodermin+ Th cells. Higher baseline frequencies of Eomesodermin+ Th cells predicted prospective one-year disability progression in a small group of secondary progressive patients. Conclusively, voxel-based morphometry analysis revealed pronounced infratentorial brain atrophy in a sub-cohort of patients with higher Eomesodermin+ Th frequencies. In summary, Eomesodermin+ Th cells may shape a dysregulated and proinflammatory immune milieu, driving disease progression and neurodegeneration in secondary progressive multiple sclerosis with potential as both biomarker and therapeutic target.
- 27 October 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (6)
Open AccessEomesodermin-expressing CD4 Th cells and association with multiple sclerosis progression and brain atrophy
Multiple sclerosis is a chronic inflammatory disease affecting the central nervous system. While treatment made huge advances, progression remains a challenge. Eomesodermin+ Th cells are associated with cytotoxicity, neuroinflammation and disease progression in secondary progressive multiple sclerosis. We performed a prospective longitudinal study over one year to investigate the role of Eomesodermin+ T cells in multiple sclerosis progression and neurodegeneration. Patients underwent detailed clinical assessment and immunophenotyping. In a subcohort of patients, cross-sectional magnetic resonance imaging using voxel-based morphometry was performed. Frequencies of Eomesodermin+ Th cells could differentiate between patients with secondary and primary progressive multiple sclerosis and correlated with B-cells in secondary progressive multiple sclerosis. Secondary progressive patients experiencing a subjective worsening of disease activity showed higher baseline frequencies of Eomesodermin+ Th cells. Higher baseline frequencies of Eomesodermin+ Th cells predicted prospective one-year disability progression in a small group of secondary progressive patients. Conclusively, voxel-based morphometry analysis revealed pronounced infratentorial brain atrophy in a sub-cohort of patients with higher Eomesodermin+ Th frequencies. In summary, Eomesodermin+ Th cells may shape a dysregulated and proinflammatory immune milieu, driving disease progression and neurodegeneration in secondary progressive multiple sclerosis with potential as both biomarker and therapeutic target.
- 1 November 2024
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 11 (6) , e200325
Cognitive Impairment, Associated Clinical Factors, and MR Volumetric Measures in Myelin Oligodendrocyte Glycoprotein-IgG–Associated Disease
Cognitive impairment is a common and challenging symptom in multiple sclerosis and neuromyelitis optica spectrum disease; however, data in myelin oligodendrocyte glycoprotein-IgG-associated disease (MOGAD) remain scarce. In this cross-sectional study, we investigated the frequency of cognitive impairment, associated clinical factors, and MRI volumetric measures in MOGAD. Participants were investigated in a single center by certified psychologists and underwent a standardized 3-T-MRI protocol. MRI data were processed with FreeSurfer for gray and white matter volume estimation, presented as a fraction of total intracranial volume. Sera screening for antineural antibodies has been conducted using cell-based assays. The following clinical factors were included in the multivariate logistic regression analysis: sex, age, overall number of previous relapses, and specifically the history of acute disseminated encephalomyelitis (ADEM)/ADEM-like episodes and other brain relapses. Thirty-two patients with MOGAD (19 female, median age 29.4 years) after a median of 2 relapses with a median EDSS of 1.0 were recruited. Seven patients (21.9%) demonstrated cognitive impairment with the most prevalent deficits in mental flexibility (16.7%), attention (11.1%-14.8%), and verbal working memory (10.3%). 72.4% suffered from fatigue and 42.9% from signs of depression, moderate to severe in 28.6%. The overall number of previous relapses (odds ratio [OR] 1.789, 95% CI 1.041-3.074) and specifically ADEM/ADEM-like episodes (OR 16.929, 95% CI 1.228-233.427) were the only clinical factors associated with cognitive impairment in a multivariate logistic regression model. Screening for antineuronal antibodies remained negative. Cerebral white matter (WM) (0.300 vs 0.317, p = 0.003) and deep gray matter (DGM) (0.036 vs 0.038, p = 0.002) volumes were reduced in patients with MOGAD compared with healthy controls (n = 32). Both cognitive impairment (0.031 vs 0.036, p = 0.003) and history of ADEM/ADEM-like episodes (0.032 vs 0.036, p = 0.006) were associated with reduced DGM volume compared with unaffected patients with MOGAD. Despite a low overall disability, every 5th patient with MOGAD experiences cognitive impairment. Cognitive impairment is associated with a higher number of relapses and particularly ADEM/ADEM-like attacks. Although both WM and DGM atrophies are apparent in MOGAD, the latter only seems to have an association with cognitive impairment.
- 1 November 2024
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 11 (6) , e200325
Cognitive Impairment, Associated Clinical Factors, and MR Volumetric Measures in Myelin Oligodendrocyte Glycoprotein-IgG–Associated Disease
Cognitive impairment is a common and challenging symptom in multiple sclerosis and neuromyelitis optica spectrum disease; however, data in myelin oligodendrocyte glycoprotein-IgG-associated disease (MOGAD) remain scarce. In this cross-sectional study, we investigated the frequency of cognitive impairment, associated clinical factors, and MRI volumetric measures in MOGAD. Participants were investigated in a single center by certified psychologists and underwent a standardized 3-T-MRI protocol. MRI data were processed with FreeSurfer for gray and white matter volume estimation, presented as a fraction of total intracranial volume. Sera screening for antineural antibodies has been conducted using cell-based assays. The following clinical factors were included in the multivariate logistic regression analysis: sex, age, overall number of previous relapses, and specifically the history of acute disseminated encephalomyelitis (ADEM)/ADEM-like episodes and other brain relapses. Thirty-two patients with MOGAD (19 female, median age 29.4 years) after a median of 2 relapses with a median EDSS of 1.0 were recruited. Seven patients (21.9%) demonstrated cognitive impairment with the most prevalent deficits in mental flexibility (16.7%), attention (11.1%-14.8%), and verbal working memory (10.3%). 72.4% suffered from fatigue and 42.9% from signs of depression, moderate to severe in 28.6%. The overall number of previous relapses (odds ratio [OR] 1.789, 95% CI 1.041-3.074) and specifically ADEM/ADEM-like episodes (OR 16.929, 95% CI 1.228-233.427) were the only clinical factors associated with cognitive impairment in a multivariate logistic regression model. Screening for antineuronal antibodies remained negative. Cerebral white matter (WM) (0.300 vs 0.317, p = 0.003) and deep gray matter (DGM) (0.036 vs 0.038, p = 0.002) volumes were reduced in patients with MOGAD compared with healthy controls (n = 32). Both cognitive impairment (0.031 vs 0.036, p = 0.003) and history of ADEM/ADEM-like episodes (0.032 vs 0.036, p = 0.006) were associated with reduced DGM volume compared with unaffected patients with MOGAD. Despite a low overall disability, every 5th patient with MOGAD experiences cognitive impairment. Cognitive impairment is associated with a higher number of relapses and particularly ADEM/ADEM-like attacks. Although both WM and DGM atrophies are apparent in MOGAD, the latter only seems to have an association with cognitive impairment.
- Open Access
- 25 July 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (8) , 2166-2175
Cortical atrophy patterns in myelin oligodendrocyte glycoprotein antibody‐associated disease
Objectives: Global brain volume changes in patients with myelin oligodendrocyte glycoprotein antibody‐associated disease compared with healthy controls (HC) could be revealed by magnetic resonance imaging, but specific atrophy patterns of cortical structures and relation to cognitive impairment are not yet comprehensively known. Thus, we aimed to investigate cortical thickness differences in patients with myelin oligodendrocyte glycoprotein antibody‐associated disease compared with HC.Methods: 3‐Tesla brain magnetic resonance imaging was performed in 23 patients with myelin oligodendrocyte glycoprotein antibody‐associated disease and 49 HC for voxel‐wise group comparisons and neuropsychological testing in patients. Surface‐based morphometry with region of interest‐based surface analysis and region of interest‐based extraction of cortical thickness was performed in patients compared with HC and in patient subgroups with and without cognitive impairment.Results: Comparing patients with myelin oligodendrocyte glycoprotein antibody‐associated disease with HC, exploratory surface‐based morphometry demonstrated cortical volume reduction in pericalcarine and lingual cortical regions. Region of interest‐based surface analysis specified reduced cortical thickness in the adjacent pericalcarine and orbitofrontal regions in myelin oligodendrocyte glycoprotein antibody‐associated disease, as well as reduced temporal cortical thickness in patients with cognitive impairment (n = 10). Patients without cognitive impairment (n = 13) showed only circumscribed cortical brain volume loss compared with HC in the pericalcarine region.Interpretation: In conclusion, cortical atrophy in myelin oligodendrocyte glycoprotein antibody‐associated disease was characterized by cortical thickness reduction in the adjacent pericalcarine and orbitofrontal regions, with a tendency of temporal thickness reduction in cognitively impaired patients.
- 25 July 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (8) , 2166-2175
Open AccessCortical atrophy patterns in myelin oligodendrocyte glycoprotein antibody‐associated disease
Objectives: Global brain volume changes in patients with myelin oligodendrocyte glycoprotein antibody‐associated disease compared with healthy controls (HC) could be revealed by magnetic resonance imaging, but specific atrophy patterns of cortical structures and relation to cognitive impairment are not yet comprehensively known. Thus, we aimed to investigate cortical thickness differences in patients with myelin oligodendrocyte glycoprotein antibody‐associated disease compared with HC.Methods: 3‐Tesla brain magnetic resonance imaging was performed in 23 patients with myelin oligodendrocyte glycoprotein antibody‐associated disease and 49 HC for voxel‐wise group comparisons and neuropsychological testing in patients. Surface‐based morphometry with region of interest‐based surface analysis and region of interest‐based extraction of cortical thickness was performed in patients compared with HC and in patient subgroups with and without cognitive impairment.Results: Comparing patients with myelin oligodendrocyte glycoprotein antibody‐associated disease with HC, exploratory surface‐based morphometry demonstrated cortical volume reduction in pericalcarine and lingual cortical regions. Region of interest‐based surface analysis specified reduced cortical thickness in the adjacent pericalcarine and orbitofrontal regions in myelin oligodendrocyte glycoprotein antibody‐associated disease, as well as reduced temporal cortical thickness in patients with cognitive impairment (n = 10). Patients without cognitive impairment (n = 13) showed only circumscribed cortical brain volume loss compared with HC in the pericalcarine region.Interpretation: In conclusion, cortical atrophy in myelin oligodendrocyte glycoprotein antibody‐associated disease was characterized by cortical thickness reduction in the adjacent pericalcarine and orbitofrontal regions, with a tendency of temporal thickness reduction in cognitively impaired patients.
- Open Access
- 18 December 2023
- Published by Springer Nature in Neuroradiology
- Vol. 66 (2) , 193-205
Automatic estimation of brain parenchymal fraction in patients with multple sclerosis: a comparison between synthetic MRI and an established automated brain segmentation software based on FSL
Purpose: We aimed to validate the estimation of the brain parenchymal fraction (BPF) in patients with multiple sclerosis (MS) using synthetic magnetic resonance imaging (SyMRI) by comparison with software tools of the FMRIB Software Library (FSL). In addition to a cross-sectional method comparison, longitudinal volume changes were assessed to further elucidate the suitability of SyMRI for quantification of disease-specific changes. Methods: MRI data from 216 patients with MS and 28 control participants were included for volume estimation by SyMRI and FSL-SIENAX. Moreover, longitudinal data from 35 patients with MS were used to compare registration-based percentage brain volume changes estimated using FSL-SIENA to difference-based calculations of volume changes using SyMRI. Results: We observed strong correlations of estimated brain volumes between the two methods. While SyMRI overestimated grey matter and BPF compared to FSL-SIENAX, indicating a systematic bias, there was excellent agreement according to intra-class correlation coefficients for grey matter and good agreement for BPF and white matter. Bland–Altman plots suggested that the inter-method differences in BPF were smaller in patients with brain atrophy compared to those without atrophy. Longitudinal analyses revealed a tendency for higher atrophy rates for SyMRI than for SIENA, but SyMRI had a robust correlation and a good agreement with SIENA. Conclusion: In summary, BPF based on data from SyMRI and FSL-SIENAX is not directly transferable because an overestimation and higher variability of SyMRI values were observed. However, the consistency and correlations between the two methods were satisfactory, and SyMRI was suitable to quantify disease-specific atrophy in MS.
- 18 December 2023
- Published by Springer Nature in Neuroradiology
- Vol. 66 (2) , 193-205
Open AccessAutomatic estimation of brain parenchymal fraction in patients with multple sclerosis: a comparison between synthetic MRI and an established automated brain segmentation software based on FSL
Purpose: We aimed to validate the estimation of the brain parenchymal fraction (BPF) in patients with multiple sclerosis (MS) using synthetic magnetic resonance imaging (SyMRI) by comparison with software tools of the FMRIB Software Library (FSL). In addition to a cross-sectional method comparison, longitudinal volume changes were assessed to further elucidate the suitability of SyMRI for quantification of disease-specific changes. Methods: MRI data from 216 patients with MS and 28 control participants were included for volume estimation by SyMRI and FSL-SIENAX. Moreover, longitudinal data from 35 patients with MS were used to compare registration-based percentage brain volume changes estimated using FSL-SIENA to difference-based calculations of volume changes using SyMRI. Results: We observed strong correlations of estimated brain volumes between the two methods. While SyMRI overestimated grey matter and BPF compared to FSL-SIENAX, indicating a systematic bias, there was excellent agreement according to intra-class correlation coefficients for grey matter and good agreement for BPF and white matter. Bland–Altman plots suggested that the inter-method differences in BPF were smaller in patients with brain atrophy compared to those without atrophy. Longitudinal analyses revealed a tendency for higher atrophy rates for SyMRI than for SIENA, but SyMRI had a robust correlation and a good agreement with SIENA. Conclusion: In summary, BPF based on data from SyMRI and FSL-SIENAX is not directly transferable because an overestimation and higher variability of SyMRI values were observed. However, the consistency and correlations between the two methods were satisfactory, and SyMRI was suitable to quantify disease-specific atrophy in MS.
- 14 December 2022
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (6) , 2489-2501
Clinical and MRI measures to identify non-acute MOG-antibody disease in adults
MRI and clinical features of myelin oligodendrocyte glycoprotein (MOG)-antibody disease may overlap with those of other inflammatory demyelinating conditions posing diagnostic challenges, especially in non-acute phases and when serologic testing for MOG antibodies is unavailable or shows uncertain results. We aimed to identify MRI and clinical markers that differentiate non-acute MOG-antibody disease from aquaporin 4 (AQP4)-antibody neuromyelitis optica spectrum disorder and relapsing remitting multiple sclerosis, guiding in the identification of patients with MOG-antibody disease in clinical practice. In this cross-sectional retrospective study, data from 16 MAGNIMS centres were included. Data collection and analyses were conducted from 2019 to 2021. Inclusion criteria were: diagnosis of MOG-antibody disease; AQP4-neuromyelitis optica spectrum disorder and multiple sclerosis; brain and cord MRI at least 6 months from relapse; and Expanded Disability Status Scale (EDSS) score on the day of MRI. Brain white matter T2 lesions, T1-hypointense lesions, cortical and cord lesions were identified. Random forest models were constructed to classify patients as MOG-antibody disease/AQP4-neuromyelitis optica spectrum disorder/multiple sclerosis; a leave one out cross-validation procedure assessed the performance of the models. Based on the best discriminators between diseases, we proposed a guide to target investigations for MOG-antibody disease. One hundred and sixty-two patients with MOG-antibody disease [99 females, mean age: 41 (±14) years, median EDSS: 2 (0–7.5)], 162 with AQP4-neuromyelitis optica spectrum disorder [132 females, mean age: 51 (±14) years, median EDSS: 3.5 (0–8)], 189 with multiple sclerosis (132 females, mean age: 40 (±10) years, median EDSS: 2 (0–8)] and 152 healthy controls (91 females) were studied. In young patients (<34 years), with low disability (EDSS < 3), the absence of Dawson’s fingers, temporal lobe lesions and longitudinally extensive lesions in the cervical cord pointed towards a diagnosis of MOG-antibody disease instead of the other two diseases (accuracy: 76%, sensitivity: 81%, specificity: 84%, P < 0.001). In these non-acute patients, the number of brain lesions < 6 predicted MOG-antibody disease versus multiple sclerosis (accuracy: 83%, sensitivity: 82%, specificity: 83%, P < 0.001). An EDSS < 3 and the absence of longitudinally extensive lesions in the cervical cord predicted MOG-antibody disease versus AQP4-neuromyelitis optica spectrum disorder (accuracy: 76%, sensitivity: 89%, specificity: 62%, P < 0.001). A workflow with sequential tests and supporting features is proposed to guide better identification of patients with MOG-antibody disease. Adult patients with non-acute MOG-antibody disease showed distinctive clinical and MRI features when compared to AQP4-neuromyelitis optica spectrum disorder and multiple sclerosis. A careful inspection of the morphology of brain and cord lesions together with clinical information can guide further analyses towards the diagnosis of MOG-antibody disease in clinical practice.
- 14 December 2022
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (6) , 2489-2501
Clinical and MRI measures to identify non-acute MOG-antibody disease in adults
MRI and clinical features of myelin oligodendrocyte glycoprotein (MOG)-antibody disease may overlap with those of other inflammatory demyelinating conditions posing diagnostic challenges, especially in non-acute phases and when serologic testing for MOG antibodies is unavailable or shows uncertain results. We aimed to identify MRI and clinical markers that differentiate non-acute MOG-antibody disease from aquaporin 4 (AQP4)-antibody neuromyelitis optica spectrum disorder and relapsing remitting multiple sclerosis, guiding in the identification of patients with MOG-antibody disease in clinical practice. In this cross-sectional retrospective study, data from 16 MAGNIMS centres were included. Data collection and analyses were conducted from 2019 to 2021. Inclusion criteria were: diagnosis of MOG-antibody disease; AQP4-neuromyelitis optica spectrum disorder and multiple sclerosis; brain and cord MRI at least 6 months from relapse; and Expanded Disability Status Scale (EDSS) score on the day of MRI. Brain white matter T2 lesions, T1-hypointense lesions, cortical and cord lesions were identified. Random forest models were constructed to classify patients as MOG-antibody disease/AQP4-neuromyelitis optica spectrum disorder/multiple sclerosis; a leave one out cross-validation procedure assessed the performance of the models. Based on the best discriminators between diseases, we proposed a guide to target investigations for MOG-antibody disease. One hundred and sixty-two patients with MOG-antibody disease [99 females, mean age: 41 (±14) years, median EDSS: 2 (0–7.5)], 162 with AQP4-neuromyelitis optica spectrum disorder [132 females, mean age: 51 (±14) years, median EDSS: 3.5 (0–8)], 189 with multiple sclerosis (132 females, mean age: 40 (±10) years, median EDSS: 2 (0–8)] and 152 healthy controls (91 females) were studied. In young patients (<34 years), with low disability (EDSS < 3), the absence of Dawson’s fingers, temporal lobe lesions and longitudinally extensive lesions in the cervical cord pointed towards a diagnosis of MOG-antibody disease instead of the other two diseases (accuracy: 76%, sensitivity: 81%, specificity: 84%, P < 0.001). In these non-acute patients, the number of brain lesions < 6 predicted MOG-antibody disease versus multiple sclerosis (accuracy: 83%, sensitivity: 82%, specificity: 83%, P < 0.001). An EDSS < 3 and the absence of longitudinally extensive lesions in the cervical cord predicted MOG-antibody disease versus AQP4-neuromyelitis optica spectrum disorder (accuracy: 76%, sensitivity: 89%, specificity: 62%, P < 0.001). A workflow with sequential tests and supporting features is proposed to guide better identification of patients with MOG-antibody disease. Adult patients with non-acute MOG-antibody disease showed distinctive clinical and MRI features when compared to AQP4-neuromyelitis optica spectrum disorder and multiple sclerosis. A careful inspection of the morphology of brain and cord lesions together with clinical information can guide further analyses towards the diagnosis of MOG-antibody disease in clinical practice.
- Open Access
- 25 August 2022
- Published by Elsevier in NeuroImage: Clinical
- Vol. 36, 103166
Relaxometry and brain myelin quantification with synthetic MRI in MS subtypes and their associations with spinal cord atrophy
- 25 August 2022
- Published by Elsevier in NeuroImage: Clinical
- Vol. 36, 103166
Open AccessRelaxometry and brain myelin quantification with synthetic MRI in MS subtypes and their associations with spinal cord atrophy
- Open Access
- 28 June 2022
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 4 (4) , fcac172
Quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging
MRI is an important diagnostic tool for evaluation of myelin content in multiple sclerosis and other CNS diseases, being especially relevant for studies investigating remyelinating pharmacotherapies. In this study, we evaluated a new synthetic MRI–based myelin estimation in methylenetetrahydrofolate reductase deficiency as a treatable primary demyelinating disorder and compared this method with established diffusion tensor imaging in both methylenetetrahydrofolate reductase deficiency patients and healthy controls. This is the first synthetic MRI–based in vivo evaluation of treatment-associated remyelination. 1.5 T synthetic MRI and 3 T diffusion MRI were obtained from three methylenetetrahydrofolate reductase deficiency patients at baseline and 6 months after therapy initiation, as well as from age-matched healthy controls (diffusion tensor imaging: n = 14, synthetic MRI: n = 9). Global and regional synthetic MRI parameters (myelin volume fraction, proton density, and relaxation rates) were compared with diffusion metrics (fractional anisotropy, mean/radial/axial diffusivity) and related to healthy controls by calculating z-scores and z-deviation maps. Whole-brain myelin (% of intracranial volume) of the index patient was reduced to 6 versus 10% in healthy controls, which recovered to a nonetheless subnormal level of 6.6% following initiation of high-dosage betaine. Radial diffusivity was higher at baseline compared with healthy controls (1.34 versus 0.79 × 10−3 mm2/s), recovering at follow-up (1.19 × 10−3 mm2/s). The index patient’s lesion volume diminished by 58% under treatment. Regional analysis within lesion area and atlas-based regions revealed lower mean myelin volume fraction (12.7Baseline/14.71Follow-up%) and relaxation rates, higher proton density, as well as lower fractional anisotropy and higher radial diffusivity (1.08 × 10−3Baseline/0.94 × 10−3Follow-up) compared with healthy controls. The highest z-scores were observed for myelin volume fraction in the posterior thalamic radiation, with greater deviation from controls at baseline and reduced deviation at follow-up. Z-deviations of diffusion metrics were less pronounced for radial and mean diffusivity than for myelin volume fraction. Z-maps for myelin volume fraction of the index patient demonstrated high deviation within and beyond lesion areas, among others in the precentral and postcentral gyrus, as well as in the cerebellum, and partial remission of these alterations at follow-up, while radial diffusivity demonstrated more widespread deviations in supra- and infratentorial regions. Concordant changes of myelin volume fraction and radial diffusivity after treatment initiation, accompanied by dramatic clinical and paraclinical improvement, indicate the consistency of the methods, while myelin volume fraction seems to characterize remyelinated regions more specifically. Synthetic MRI–based myelin volume fraction provides myelin estimation consistent with changes of diffusion metrics to monitor short-term myelin changes on individual patient level.
- 28 June 2022
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 4 (4) , fcac172
Open AccessQuantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging
MRI is an important diagnostic tool for evaluation of myelin content in multiple sclerosis and other CNS diseases, being especially relevant for studies investigating remyelinating pharmacotherapies. In this study, we evaluated a new synthetic MRI–based myelin estimation in methylenetetrahydrofolate reductase deficiency as a treatable primary demyelinating disorder and compared this method with established diffusion tensor imaging in both methylenetetrahydrofolate reductase deficiency patients and healthy controls. This is the first synthetic MRI–based in vivo evaluation of treatment-associated remyelination. 1.5 T synthetic MRI and 3 T diffusion MRI were obtained from three methylenetetrahydrofolate reductase deficiency patients at baseline and 6 months after therapy initiation, as well as from age-matched healthy controls (diffusion tensor imaging: n = 14, synthetic MRI: n = 9). Global and regional synthetic MRI parameters (myelin volume fraction, proton density, and relaxation rates) were compared with diffusion metrics (fractional anisotropy, mean/radial/axial diffusivity) and related to healthy controls by calculating z-scores and z-deviation maps. Whole-brain myelin (% of intracranial volume) of the index patient was reduced to 6 versus 10% in healthy controls, which recovered to a nonetheless subnormal level of 6.6% following initiation of high-dosage betaine. Radial diffusivity was higher at baseline compared with healthy controls (1.34 versus 0.79 × 10−3 mm2/s), recovering at follow-up (1.19 × 10−3 mm2/s). The index patient’s lesion volume diminished by 58% under treatment. Regional analysis within lesion area and atlas-based regions revealed lower mean myelin volume fraction (12.7Baseline/14.71Follow-up%) and relaxation rates, higher proton density, as well as lower fractional anisotropy and higher radial diffusivity (1.08 × 10−3Baseline/0.94 × 10−3Follow-up) compared with healthy controls. The highest z-scores were observed for myelin volume fraction in the posterior thalamic radiation, with greater deviation from controls at baseline and reduced deviation at follow-up. Z-deviations of diffusion metrics were less pronounced for radial and mean diffusivity than for myelin volume fraction. Z-maps for myelin volume fraction of the index patient demonstrated high deviation within and beyond lesion areas, among others in the precentral and postcentral gyrus, as well as in the cerebellum, and partial remission of these alterations at follow-up, while radial diffusivity demonstrated more widespread deviations in supra- and infratentorial regions. Concordant changes of myelin volume fraction and radial diffusivity after treatment initiation, accompanied by dramatic clinical and paraclinical improvement, indicate the consistency of the methods, while myelin volume fraction seems to characterize remyelinated regions more specifically. Synthetic MRI–based myelin volume fraction provides myelin estimation consistent with changes of diffusion metrics to monitor short-term myelin changes on individual patient level.
- Open Access
- 1 July 2021
- Published by Korean Society of Interventional Neuroradiology in Neurointervention
- Vol. 16 (2) , 190-193
Usefulness of Computed Tomographic Perfusion Imaging for Appropriate Diagnosis of Acute Cerebral Vessel Occlusion in Case of Anatomic Variations of the Circle of Willis
Mechanical thrombectomy (MT) is an effective treatment in patients with acute ischemic stroke (AIS) due to emergent large-vessel occlusion in the anterior circulation. Occlusion of the anterior cerebral artery (ACA) affects up to 15% of these patients. Here we report a case of an elderly patient with an successful MT of an embolic A2-segment occlussion with the anatomic variation of a triplication. Triplication of ACA is a rare anatomical variation, and the occlusion could have been easily overlooked in case of not performing the CT-perfusion (CTP) sequences. As anatomical variations of the circle of Willis are present in most subjects, CTA alone might be limited in the acute setting, particularly for young residents performing the first view on call. This case highlights the importance of including CTP in the initial CT-diagnostic algorithm in AIS patients who are basically eligible for recanalization therapies, irrespective of inconspicuous initial findings in CTA.
- 1 July 2021
- Published by Korean Society of Interventional Neuroradiology in Neurointervention
- Vol. 16 (2) , 190-193
Open AccessUsefulness of Computed Tomographic Perfusion Imaging for Appropriate Diagnosis of Acute Cerebral Vessel Occlusion in Case of Anatomic Variations of the Circle of Willis
Mechanical thrombectomy (MT) is an effective treatment in patients with acute ischemic stroke (AIS) due to emergent large-vessel occlusion in the anterior circulation. Occlusion of the anterior cerebral artery (ACA) affects up to 15% of these patients. Here we report a case of an elderly patient with an successful MT of an embolic A2-segment occlussion with the anatomic variation of a triplication. Triplication of ACA is a rare anatomical variation, and the occlusion could have been easily overlooked in case of not performing the CT-perfusion (CTP) sequences. As anatomical variations of the circle of Willis are present in most subjects, CTA alone might be limited in the acute setting, particularly for young residents performing the first view on call. This case highlights the importance of including CTP in the initial CT-diagnostic algorithm in AIS patients who are basically eligible for recanalization therapies, irrespective of inconspicuous initial findings in CTA.